Tiffany Tanaka is an Oncology physician affiliated with UC San Diego Health System. OpenAlex indexes 63 publications with 1,347 citations (h-index 16).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
402 Dickinson St
Suite 380
San Diego, CA 921036902
Telephone
619-290-7497Registry record last updated 24 Jan 2017.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
- Geron CorporationProgram year202510 payments
- Cycle Pharmaceuticals IncProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
45.9%Kinase inhibitor22.2%Bosulif41%Imatinib Mesylate31%Jakafi29%Part D<11 patientsAntimetabolite18.3%Hydroxyurea77%Droxia23%Part D<11 patients+ 1 more class in this area
Anti-infectives
24.4%Azole Antifungal5.9%Fluconazole54%Posaconazole46%Part D<11 patientsTriazole and tetrazole derivatives4.1%Cresemba100%Part D<11 patients+ 4 more classes in this area
Dermatology
14.1%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor14.1%Acyclovir100%Part D≥19 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 2.2025
Journal of the National Comprehensive Cancer Network
2025 - Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Andrew Lowy, MD
UC San Diego Health System
Roger Spragg, MD
UC San Diego Health System
Rafael Bejar, MD, PhD
UC San Diego Health System
Zea Borok, MD
UC San Diego Health System
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”